Longevity Lab Report
← All supplements

DIM (Diindolylmethane)

An estrogen-metabolite shifter whose trials measure ratios, not results

D+

Evidence grade

D

Worth it

$10-20/month

Typical cost

DoseTrials used 100 to 300 mg a day, most often 200 mg, of formulated DIM (absorption-enhanced preparations dominate the literature, which is why raw dose comparisons across products mislead). No dose has been connected to a clinical outcome.

BasisThe human literature is biomarker studies: DIM changes estrogen metabolite ratios (2-hydroxyestrone relative to 16-alpha-hydroxyestrone) at 100 to 300 mg a day, consistently, in small samples.

DIM is a metabolite of indole-3-carbinol from cruciferous vegetables, sold for estrogen metabolism and hormone balance. We grade DIM (Diindolylmethane) D+ on evidence and D for worth-it at about $10-20 per month.

Questions

Answers come straight from this record's graded evidence.

Does DIM lower estrogen?

That is not what the trials show. DIM reliably shifts urinary estrogen metabolites toward 2-hydroxylation (raising 2-hydroxyestrone relative to 16-alpha-hydroxyestrone) at 100 to 300 mg a day in small human trials, and our record grades that biomarker effect C- inside a D+ record. A ratio shift is not an estrogen reduction, and no trial has connected a DIM-driven shift to cancer prevention, symptom relief, or any clinical endpoint; the compound's one randomized outcome trial, in cervical dysplasia, was null on its primary outcome.

the marketing vocabulary (balance, detox, lower estrogen) describes outcomes the literature never tested; what was tested is a number, and the number's meaning is unproven.

Is DIM safe with hormone therapy?

Nobody knows, and that absence is the answer: for a compound sold to alter estrogen metabolism, the evidence alongside hormone therapies is absent rather than reassuring, so anyone on hormone therapy should treat DIM as a question for their clinician before use, not as a settled combination. The second caution is mechanical: DIM induces CYP enzymes, so effects on the metabolism of prescription drugs are plausible and under-studied. In trials DIM was generally tolerated (gastrointestinal upset, headache, darkened urine from metabolites), and data in pregnancy are insufficient: avoid. Our record grades DIM D+ on evidence and D for worth-it at $10 to $20 a month.

a product whose purpose is to move hormone metabolism carries a higher burden of proof beside hormone therapy, and that proof does not exist yet in either direction.

What it does

DIM is a metabolite of indole-3-carbinol from cruciferous vegetables, sold for estrogen metabolism and hormone balance. It induces CYP1A enzymes and reliably shifts urinary estrogen metabolites toward 2-hydroxylation in small human trials. What no trial has shown is that the shift changes any outcome a person can feel or a clinician can measure: the one randomized outcome trial in the file, in cervical dysplasia, found no significant benefit on its primary outcome.

What the research says

  • Shifts estrogen metabolism toward 2-hydroxylation

    Evidence: C-. The biomarker effect is real and replicated in small trials; it is a ratio change, not a health outcome, and the record grades it as exactly that.

  • Improves cervical dysplasia (CIN)

    Evidence: D. The randomized trial found no significant benefit on its primary outcome; the claim is carried so the null is on the record, not because the benefit is supported.

  • Relieves menopause or hormone-balance symptoms

    Evidence: D. No adequate trials exist for the symptom claims the marketing leads with.

The human literature is biomarker studies: DIM changes estrogen metabolite ratios (2-hydroxyestrone relative to 16-alpha-hydroxyestrone) at 100 to 300 mg a day, consistently, in small samples. The ratio is a surrogate with no trial connecting a DIM-driven change to cancer prevention, symptom relief, or any clinical endpoint, and the compound's one outcome trial (cervical intraepithelial neoplasia) was null on its primary outcome. A reliable effect on a number nobody has shown to matter, with the outcome trial negative, grades D+.

Is it worth it?

DWorth it

The purchase buys a measurable change in a urinary ratio that no trial has connected to a result, sold in the vocabulary of outcomes (balance, detox) the literature never tested. The one outcome trial in the file was null. That is a D purchase.

Typical cost

$10-20/month

Common form, not a brand recommendation

Dosage context verified

Trials used 100 to 300 mg a day, most often 200 mg, of formulated DIM (absorption-enhanced preparations dominate the literature, which is why raw dose comparisons across products mislead). No dose has been connected to a clinical outcome.

The worth-it ranking

DIM (Diindolylmethane) sits outside the worth-it ranking of 38.

DIM (Diindolylmethane) sits outside that ranking of 38. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.

  1. 1AWorth itCreatine evidence A-~$5-10/mo
  2. 2AWorth itCaffeine evidence B+~$5-10/mo
  3. 3AWorth itVitamin D evidence B~$5-8/mo

See the full ranking of 38 →

When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.

Safety notes

The safety centre is interaction and absence. DIM induces CYP enzymes, so effects on the metabolism of prescription drugs are plausible and under-studied, and anyone on medication metabolized by CYP1A or related pathways should treat DIM as an interaction question for their clinician. For a compound sold to alter estrogen metabolism, the evidence in hormone-sensitive conditions and alongside hormone therapies is absent rather than reassuring, and that absence is the caution. Generally tolerated in trials (gastrointestinal upset, headache, darkened urine from metabolites). Insufficient data in pregnancy: avoid.

Changelog

Last updated 2026-11-10

  • 2026-11-10|Initial grading: evidence D+, worth-it D. The record's core fact is the missing outcome trial: DIM reliably shifts an estrogen metabolite ratio no study has tied to a clinical result, and its one randomized outcome trial, in cervical dysplasia, was null on its primary outcome.

The week's longevity and biohacking news.

Every story graded against the evidence. Free. Unsubscribe anytime.

The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.

Every grade follows a published rubric. Sponsors do not influence findings or grades.